Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter

American Journal of Cardiology

Volumn 113, Issue 8, 2014, Pages 1362-1363

  Yadlapati, Ajay ^a   Groh, Christopher ^a   Passman, Rod ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DABIGATRAN; RIVAROXABAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIRECT CURRENT CARDIOVERSION; DRUG SAFETY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MORPHOLINES; RETROSPECTIVE STUDIES; THIOPHENES; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897449184     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.12.044     Document Type: Article

References (10)

1. W. Gibson, A.J. Linenthal, L.R. Norman, M.H. Paul, and P.M. Zoll The effect of external electric currents on the heart; control of cardiac rhythm and induction and termination of cardiac arrhythmias Circulation 14 1956 745 756
2. J.W. Kinch, and R. Davidoff Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies Arch Intern Med 155 1995 1353 1360
3. A.Z. Arnold, M.J. Mick, R.P. Mazurek, F.D. Loop, and R.G. Trohman Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 19 1992 851 855
4. D.M. Weinberg, and J. Mancini Anticoagulation for cardioversion of atrial fibrillation Am J Cardiol 63 1989 745 746
5. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and Publications Committees of the ACUTE Study Am J Cardiol 81 1998 877 883
6. N.H. Hauel, H. Nar, H. Priepke, U. Ries, J.M. Stassen, and W. Wienen Structure-based design of novel potent nonpeptide thrombin inhibitors J Med Chem 45 2002 1757 1766
7. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
8. R. Kreutz Pharmacodynamic and pharmacokinetic basics of rivaroxaban Fundam Clin Pharmacol 26 2012 27 32
9. A.R. Harrington, E.P. Armstrong, P.E. Nolan Jr., and D.C. Malone Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
10. J.V. Freeman, R.P. Zhu, D.K. Owens, A.M. Garber, D.W. Hutton, A.S. Go, P.J. Wang, and M.P. Turakhia Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11